v3.23.1
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2021 $ 15,436 $ 18 $ (3,143) $ 18,305 $ 3,127 $ (2,899) $ 28
Beginning balance (in shares) at Dec. 31, 2021   1,768          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,490 $ 0 0 0 4,490 0 0
Other comprehensive income (loss), net of tax (85) 0 0 0 0 (85) 0
Dividends declared (2,514) 0 0 0 (2,514) 0 0
Purchases of treasury stock (1,470) $ 0 (1,470) 0 0 0 0
Purchases of treasury stock (in shares)   (10)          
Stock-based compensation plans and other 454 $ 0 28 426 0 0 0
Stock-based compensation plans and other (in shares)   9          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Mar. 31, 2022 16,314 $ 18 (4,585) 18,731 5,103 (2,984) 31
Ending balance (in shares) at Mar. 31, 2022   1,767          
Beginning balance at Dec. 31, 2022 17,287 $ 18 (4,594) 19,245 4,784 (2,199) 33
Beginning balance (in shares) at Dec. 31, 2022   1,769          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 239 $ 0 0 0 239 0 0
Other comprehensive income (loss), net of tax (33) 0 0 0 0 (33) 0
Dividends declared (2,630) 0 0 0 (2,630) 0 0
Purchases of treasury stock (1,955) $ 0 (1,955) 0 0 0 0
Purchases of treasury stock (in shares)   (12)          
Stock-based compensation plans and other 399 $ 0 25 374 0 0 0
Stock-based compensation plans and other (in shares)   7          
Change in noncontrolling interest (4) $ 0 0 0 0 0 (4)
Ending balance at Mar. 31, 2023 $ 13,303 $ 18 $ (6,524) $ 19,619 $ 2,393 $ (2,232) $ 29
Ending balance (in shares) at Mar. 31, 2023   1,764